Tuesday, 12 October, 2021
We are ready for the next step!
In partnership with founders and management, ArchiMed will finance a 10-fold expansion of Xpress Biologics’ production capacity based on the implementation of GMP services.
With ArchiMed’s backing, Xpress Biologics will be able to expand plasmid DNA production, taking a bigger share of the cell and gene therapy market and following recent mRNA, Covid-19 and gene therapy breakthroughs.
This will allow us to expand our services to our customers in clinical phases, with a particular focus on internationalizing distribution in the US and in the Asia-Pacific region.
